Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
Terminated
Amgen
Phase 3
2011-02-01
This study is being conducted to learn about the safety and risks of using talimogene
laherparepvec to treat patients with head and neck cancer and to see if talimogene
laherparepvec and chemoradiation together can destroy the tumours versus the use of
chemoradiation alone. This study may provide information on the usefulness of talimogene
laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
Terminated
BioVex Limited
Phase 3
2011-02-01
This study is being conducted to learn about the safety and risks of using talimogene
laherparepvec to treat patients with head and neck cancer and to see if talimogene
laherparepvec and chemoradiation together can destroy the tumours versus the use of
chemoradiation alone. This study may provide information on the usefulness of talimogene
laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.
Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
Active, not recruiting
Amgen
Phase 1
2017-03-07
There are 2 fold of purposes for this study. 1 is to evaluate safety and tolerability and the
other is to study the anti-tumor effects of talimogene laherparepvec in Japanese participants
with unresectable stage IIIB-IV malignant melanoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
